艾拉戈利治疗子宫内膜异位症:并非所有闪光都是金子
本文评述美国食品药品监督管理局批准的口服非肽类促性腺激素释放激素拮抗剂艾拉戈利用于子宫内膜异位症相关中重度疼痛。作者指出其疗效仅在安慰剂对照解释性试验中验证,低剂量不持续抑制排卵、高剂量长期使用需反向添加治疗,且年费用约10000美元可能影响依从性与公平性。
要点
- 艾拉戈利疗效仅在安慰剂对照解释性试验中证实,尚缺乏与低剂量激素避孕药及孕激素的实用性对比试验。
- 低剂量艾拉戈利不持续抑制排卵,治疗所致闭经期间应使用非激素避孕并连续尿妊娠试验排除意外妊娠。
- 高剂量长期控制严重疼痛时应加用反向添加治疗,类似使用促性腺激素释放激素激动剂时的方案。
核心结论
- 艾拉戈利在内分泌和药理学特性上可视为新药,但其靶点仍是改变激素环境,未针对子宫内膜异位症的致病机制。
- 鉴于子宫内膜异位症的雌激素依赖性,减少副作用可能意味着疼痛缓解程度相应降低。
- 艾拉戈利的疗效迄今仅在安慰剂对照解释性试验中证实,应规划将其与低剂量激素避孕药和孕激素比较的实用性试验以验证增量获益。
- 艾拉戈利的价格可能影响患者依从性,进而影响临床有效性。
研究设计与样本
- 本文为针对艾拉戈利治疗子宫内膜异位症的评述性文章,未报告系统检索范围或原始研究数据。
主要发现
- 艾拉戈利获美国食品药品监督管理局批准用于子宫内膜异位症相关中重度疼痛。
- 艾拉戈利获得的卵巢抑制程度呈剂量依赖性,可通过调节低雌激素水平来缓解疼痛并限制副作用。
- 使用低剂量艾拉戈利时排卵未被持续抑制,患者应使用非激素避孕系统并连续进行尿妊娠试验,以排除治疗所致闭经期间的意外妊娠。
- 长期使用高剂量艾拉戈利控制严重疼痛时,应加用反向添加治疗,类似使用促性腺激素释放激素激动剂时的处方。
- 在美国,制造商艾伯维公司将艾拉戈利(OrilissaTM)定价约为每年10000美元,即每月845美元。
关键数值与推荐
- 低剂量艾拉戈利不持续抑制排卵,治疗所致闭经期间应使用非激素避孕并连续尿妊娠试验排除意外妊娠。
- 高剂量长期控制严重疼痛时应加用反向添加治疗,类似促性腺激素释放激素激动剂使用时的方案。
临床怎么用
- 作者认为,低剂量艾拉戈利治疗期间应使用非激素避孕系统并连续尿妊娠试验以排除意外妊娠。
- 作者认为,长期高剂量艾拉戈利控制严重疼痛时应加用反向添加治疗,类似促性腺激素释放激素激动剂的方案。
- 作者建议规划实用性试验,比较艾拉戈利与低剂量激素避孕药和孕激素,以验证其相对于当前标准治疗的增量获益。
局限性
- 艾拉戈利的疗效迄今仅在安慰剂对照解释性试验中证实。
- 低剂量艾拉戈利不持续抑制排卵可能带来意外妊娠风险。
- 高剂量长期使用需加用反向添加治疗。
- 艾拉戈利价格高昂可能影响患者依从性和临床有效性。
- 作者建议开展实用性试验以验证增量获益,提示现有证据限于解释性试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Elagolix, an orally active non-peptidic GnRH antagonist, has been approved by the Food and Drug Administration for the management of moderate to severe pain associated with endometriosis. As the degree of ovarian suppression obtained with elagolix is dose-dependent, pain relief may be achieved by modulating the level of hypo-oestrogenism while limiting side effects. Elagolix may thus be considered a novelty in terms of its endocrine and pharmacological properties but not for its impact on the pathogenic mechanisms of endometriosis, as the target of this new drug is, yet again, alteration of the hormonal milieu. Given the oestrogen-dependent nature of endometriosis, a reduction of side effects may imply a proportionate decrease in pain relief. Furthermore, if low elagolix doses are used, ovulation is not consistently inhibited, and patients should use non-hormonal contraceptive systems and perform serial urine pregnancy tests to rule out unplanned conception during periods of treatment-induced amenorrhoea. If high elagolix doses are used to control severe pain for long periods of time, add-back therapies should be added, similar to that prescribed when using GnRH agonists. To date, the efficacy of elagolix has only been demonstrated in placebo-controlled explanatory trials. Pragmatic trials comparing elagolix with low-dose hormonal contraceptives and progestogens should be planned to verify the magnitude of the incremental benefit, if any, of this GnRH antagonist over currently used standard treatments. The price of elagolix may impact on patient adherence and, hence, on clinical effectiveness. In the USA, the manufacturer AbbVie Inc. priced elagolix (OrilissaTM) at around $10 000 a year, i.e. $845 per month. When faced with unaffordable treatments, some patients may choose to forego care. If national healthcare systems are funded by the tax payer, the approval and the use of a new costly drug to treat a chronic condition, such as endometriosis, means that some finite financial resources will be diverted from other areas, or that similar patients will not receive the same level of care. Thus, defining the overall 'value' of a new drug for endometriosis also has ethical implications, and trade-offs between health outcomes and costs should be carefully weighed up.
引用
- Vercellini P, Viganò P, Barbara G, et al. Elagolix for endometriosis: all that glitters is not gold. Hum Reprod. 2019. PMID: 30551159. doi:10.1093/humrep/dey368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。